First Wave BioPharma shares are trading higher after the company announced license agreement for capeserod from Sanofi.
Portfolio Pulse from Benzinga Newsdesk
First Wave BioPharma has entered into a license agreement for capeserod with Sanofi, leading to a rise in its share prices.
September 14, 2023 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
First Wave BioPharma's stock is trading higher after the company announced a license agreement for capeserod with Sanofi.
The license agreement for capeserod with Sanofi is a positive development for First Wave BioPharma. This could potentially lead to increased revenues and profitability for the company, which is likely why the stock is trading higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100